Multiple Myeloma
January 2017 Issue

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Multiple Myeloma abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Multiple Myeloma. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Multiple Myeloma. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Multiple Myeloma every 3 months. Thank you for your ongoing subscription to this publication.

Elliot Jacob, Ph.D.
Vice-President - Content, Inc.

1:Multiple myeloma treatment at relapse after autologous stem cell transplantation: A practical analysis.
Authors:Malard F, Harousseau JL, Mohty M
Institution:Department of Haematology, Saint Antoine Hospital, Paris, France; INSERM UMRs 938, Paris, France; Universite Pierre et Marie Curie, Paris, France. Electronic address:; Centre Catherine de Sienne, Nantes, France.
Journal:Cancer Treat Rev. 2017 Jan;52:41-47. doi: 10.1016/j.ctrv.2016.11.005. Epub 2016 Nov 15.

2:Multiple myeloma: managing a complex blood cancer.
Authors:Dowling M, Kelly M, Meenaghan T
Institution:School of Nursing and Midwifery, National University of Ireland, Galway, Ireland. Offaly, Ireland. Ireland.
Journal:Br J Nurs. 2016 Sep 8;25(16):S18-28. doi: 10.12968/bjon.2016.25.S18.

3:Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
Authors:Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P
Institution:From the Department of Hematology, University of Turin, Turin, Italy (A.P.); the Division of Hematology and Medical Oncology, Mayo Clinic Florida, Jacksonville (A.C.-K.); Universitaetsklinikum Tuebingen der Eberhard-Karls-Universitaet, Abteilung fuer Innere Medizin II, Tuebingen (K.W.), and University Medical Center of the Johannes Gutenberg-University, Third Department of Medicine, Mainz (M.M.) - both in Germany; Winship Cancer Institute, Emory University, Atlanta (A.K.N.); the Department of Hematology and Stem Cell Transplantation, St. Laszlo Hospital, Semmelweis University, Budapest, Hungary (T.M.); Ankara University, Department of Hematology, Ankara, Turkey (M.B.); Clinical Department of Hematology, 1st Medical Department, Charles University in Prague, Prague, Czech Republic (I.S.); Irmandade Da Santa Casa De Misericordia De Sao Paulo, Sao Paulo (V.H.); University Hospital of Salamanca-Instituto de Investigacion Biomedica de Salamanca, Salamanca, Spain (M.V.M.); Weill Cornell Medical College, New York (T.M.M.); Janssen Research and Development, Spring House, PA (M.Q., X.Q., T.A.); Janssen Research and Development, Raritan, NJ (J.S., H.A.); Janssen Research and Development, Beerse, Belgium (W.D.); Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, VIC, Australia (A.S.); and the Department of Hematology, Erasmus MC, Rotterdam, the Netherlands (P.S.).
Journal:N Engl J Med. 2016 Aug 25;375(8):754-66. doi: 10.1056/NEJMoa1606038.

4:Immunoglobulin D Multiple Myeloma: Disease Profile, Therapeutic Response, and Survival.
Authors:Wang GR, Sun WJ, Chen WM, Huang ZX, Zhang JJ, An N, Shen M, Li X
Institution:Department of Hematology and Oncology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Journal:Acta Haematol. 2016;136(3):140-6. doi: 10.1159/000446599. Epub 2016 Jul 14.

5:Efficacy and safety of denosumab in multiple myeloma.
Authors:Kitagawa J, Shibata Y, Matsumoto T, Nakamura N, Nakamura H, Ninomiya S, Nannya Y, Hara T, Tsurumi H
Institution:Department of Hematology, Gifu University Graduate School of Medicine.
Journal:Rinsho Ketsueki. 2016 May;57(5):592-6. doi: 10.11406/rinketsu.57.592.

6:Novel Combination Treatments in Multiple Myeloma.
Authors:Nooka AK, Lonial S
Journal:Oncology (Williston Park). 2016 May;30(5):451-65.

7:Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Authors:Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Velde H, Richardson PG
Institution:From University Hospital Hotel Dieu, Nantes (P.M., C.T.), the Department of Hematology, Institut Paoli-Calmettes, Marseille (A.-M.S.), and the Department of Hematology and Cell Therapy, Hospital Saint Antoine, Paris (L.G.) - all in France; the Department of Haematology and Stem Cell Transplantation, St. Istvan and St. Laszlo Hospital, 3rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary (T.M.); the Department of Haemato-oncology and Bone Marrow Transplantation, Medical University of Lublin, and St. John's Cancer Center, Lublin, Poland (N.G.); Southern Alberta Cancer Research Institute, University of Calgary, Calgary (N.J.B.), and the Division of Hematology, Department of Medicine, University of Alberta, Edmonton (I.S.) - both in Canada; the Department of Hematology, Skane University Hospital, Lund University, Lund, Sweden (M.H.); Hematology and Oncology, University Hospital Brno, Brno, Czech Republic (L.P.); the Department of Haematology, Christchurch Hospital, Christchurch (P. Ganly), the Department of Haematology, Palmerston North Hospital, Palmerston North, Manawatu (B.W.B.), the Department of Haematology, Middlemore Hospital, Auckland (S.R.J.), and the Department of Haematology, North Shore Hospital, Auckland (D.R.S.) - all in New Zealand; the Department of Hematology, University Hospital Rigshospitalet, Copenhagen (P. Gimsing); Myeloma Unit, Division of Hematology, University of Turin, Turin (A.P.), and Seragnoli Institute of Haematology, Bologna University School of Medicine, St. Orsola-Malpighi University Hospital, Bologna (M.C.) - both in Italy; the Division of Hematology, Mayo Clinic, Rochester, MN (S.K., F.K.B.); and Dana-Farber Cancer Institute, Boston (J.P.L., P.G.R.), and Millennium Pharmaceuticals, Cambridge (D.T.B., J.L., A.D.B., A.-M.H., H.V.) - both in Massachusetts.
Journal:N Engl J Med. 2016 Apr 28;374(17):1621-34. doi: 10.1056/NEJMoa1516282.

8:Bortezomib for the treatment of multiple myeloma.
Authors:Scott K, Hayden PJ, Will A, Wheatley K, Coyne I
Institution:School of Nursing & Midwifery, Trinity College Dublin, 24 D'Olier St, Dublin, Ireland.
Journal:Cochrane Database Syst Rev. 2016 Apr 20;4:CD010816. doi: 10.1002/14651858.CD010816.pub2.

9:Myeloma Is Not a Single Disease.
Authors:Lonial S, Nooka AK
Institution:Emory University School of Medicine, Atlanta, GA
Journal:J Oncol Pract. 2016 Apr;12(4):287-92. doi: 10.1200/JOP.2016.010926.

10:Update of thrombosis in multiple myeloma.
Authors:Leebeek FW
Institution:Department of Hematology, Erasmus University Medical Center Rotterdam, the Netherlands. Electronic address:
Journal:Thromb Res. 2016 Apr;140 Suppl 1:S76-80. doi: 10.1016/S0049-3848(16)30103-7.

11:NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016.
Authors:Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, Kumar SK, Liedtke M, Lunning M, Raje N, Reu FJ, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R
Institution:From Dana-Farber/Brigham and Women's Cancer Center; Moffitt Cancer Center; Huntsman Cancer Institute at the University of Utah; University of Michigan Comprehensive Cancer Center; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; UC San Diego Moores Cancer Center; Fox Chase Cancer Center; Duke Cancer Institute; University of Alabama at Birmingham Comprehensive Cancer Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; Roswell Park Cancer Institute; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Vanderbilt-Ingram Cancer Center; City of Hope Comprehensive Cancer Center; Mayo Clinic Cancer Center; Stanford Cancer Institute; Fred & Pamela Buffett Cancer Center; Massachusetts General Hospital Cancer Center; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; The University of Texas MD Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; and National Comprehensive Cancer Network.
Journal:J Natl Compr Canc Netw. 2016 Apr;14(4):389-400.

12:Treatment of relapsed and refractory multiple myeloma.
Authors:Sonneveld P, Broijl A
Institution:Erasmus MC Cancer Institute, Department of Hematology, Rm Na824, Rotterdam, the Netherlands Netherlands.
Journal:Haematologica. 2016 Apr;101(4):396-406. doi: 10.3324/haematol.2015.129189.

13:Panobinostat: A histone deacetylase inhibitor for the treatment of relapsed or refractory multiple myeloma.
Authors:Wahaib K, Beggs AE, Campbell H, Kodali L, Ford PD
Institution:Department of Pharmacy Practice, Belmont University College of Pharmacy, Nashville, TN. Nashville, TN. Nashville, TN. Nashville, TN.
Journal:Am J Health Syst Pharm. 2016 Apr 1;73(7):441-50. doi: 10.2146/ajhp150487.

14:The effects of proteasome inhibitors on bone remodeling in multiple myeloma.
Authors:Zangari M, Suva LJ
Institution:Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA. Electronic address: Arkansas for Medical Sciences, Little Rock, AR, USA.
Journal:Bone. 2016 May;86:131-8. doi: 10.1016/j.bone.2016.02.019. Epub 2016 Mar 3.

15:Management of Multiple Myeloma with Second-Generation Antibody-Drug Conjugates.
Authors:Robak P, Robak T
Institution:Department of Experimental Hematology, Medical University of Lodz, Lodz, Poland. Poland.
Journal:BioDrugs. 2016 Apr;30(2):87-93. doi: 10.1007/s40259-016-0165-6.

16:Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.
Authors:Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, Belch A, Krishnan A, Vescio RA, Mateos MV, Mazumder A, Orlowski RZ, Sutherland HJ, Blade J, Scott EC, Oriol A, Berdeja J, Gharibo M, Stevens DA, LeBlanc R, Sebag M, Callander N, Jakubowiak A, White D, de la Rubia J, Richardson PG, Lisby S, Feng H, Uhlar CM, Khan I, Ahmadi T, Voorhees PM
Institution:Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA. Electronic address: and Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Northwestern University Feinberg School of Medicine, Chicago, IL, USA. Institute, Los Angeles, CA, USA. Salamanca, Salamanca, Spain. Center, Houston, TX, USA. Vancouver, BC, Canada. Barcelona, Barcelona, Spain. Pujol, Barcelona, Spain. Rutgers, State University of New Jersey, New Brunswick, NJ, USA. Canada. University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Journal:Lancet. 2016 Apr 9;387(10027):1551-60. doi: 10.1016/S0140-6736(15)01120-4. Epub 2016 Jan 7.

17:Allogeneic stem cell transplantation for multiple myeloma: is there a future?
Authors:Dhakal B, Vesole DH, Hari PN
Institution:Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA. USA. USA.
Journal:Bone Marrow Transplant. 2016 Apr;51(4):492-500. doi: 10.1038/bmt.2015.325. Epub 2016 Jan 4.

18:Favorable long-term outcome of patients with multiple myeloma using a frontline tandem approach with autologous and non-myeloablative allogeneic transplantation.
Authors:Ahmad I, LeBlanc R, Cohen S, Lachance S, Kiss T, Sauvageau G, Roy DC, Busque L, Delisle JS, Bambace N, Bernard L, Sabry W, Roy J
Institution:Division of Hematology and Medical Oncology, Department of Medicine, Hopital Maisonneuve-Rosemont, Universite de Montreal, Montreal, Quebec, Canada.
Journal:Bone Marrow Transplant. 2016 Apr;51(4):529-35. doi: 10.1038/bmt.2015.319. Epub 2015 Dec 21.

19:Clinical features and survival of 338 multiple myeloma patients treated with hematopoietic stem cell transplantation or conventional chemotherapy.
Authors:Perez R, Duran MS, Mayans J, Soler A, Castillo I, Jurado M, Ribas P, Menchaca Echevarria MC, Hernandez MT, Lopez Garcia-Carreno MD, Echeveste Gutierrez A, Bailen Garcia A, Lopez S, Baquero J, Ramirez G
Institution:Hospital Universitario Virgen de Arrixaca, Murcia, Spain. Spain.
Journal:Eur J Haematol. 2016 Apr;96(4):417-24. doi: 10.1111/ejh.12611. Epub 2015 Nov 1.

20:Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma.
Authors:Penalver FJ, Delgado J, Loscertales J, Sastre JL, Pena A, Olave MT, Osorio S, de la Fuente A, Salar A, Grande C, Perez Ceballos E, Deben G, Echeveste A, Casado F, de la Rubia J, Lahuerta JJ, Mateos MV
Institution:Department of Hematology, Hospital Universitario Fundacion Alcorcon, Alcorcon, Madrid, Spain. Spain. Spain.
Journal:Eur J Haematol. 2016 May;96(5):532-40. doi: 10.1111/ejh.12633. Epub 2015 Aug 9.

For a FREE PREVIEW of the Medifocus Guidebook on Multiple Myeloma click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Multiple Myeloma click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

Get the Medifocus Guidebook on Multiple Myeloma...
at a Special 20% Discount

Medifocus Guidebook on Multiple Myeloma

Updated: January 29, 2017
189 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
  • Timely, up to date content with free guidebook updates for 1 year.
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
  • Over 130,000 Guidebooks Sold
  • 100% Risk Free Money Back Guarantee


The Medifocus Guidebook on Multiple Myeloma is available in the following two convenient formats:


Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook


Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook

Order by Phone

Call Toll Free in the U.S.

From Outside the U.S.

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders


Coupon Expires: April 25, 2017

What Our Customers Are Saying...

"The information in your MediFocus Guidebook on Multiple Myeloma was extremely useful. Thank you for providing this service."
Milwaukee, Wisconsin

"I purchased the MediFocus Guidebook on Multiple Myeloma for my mother and it was a great help because it helped us to understand more about the disease, the causes, and the treatment options. Although there is no cure, it has helped us cope with the situation and helped us figure out how we can live with the disease."
New York, New York

"My oncologist borrowed my copy of the MediFocus Guidebook on Multiple Myeloma and found it very useful in his work. He intends to contact your office."
Miami Beach, Florida

Medifocus Digest Alert is published monthly by Medifocus, Inc.
6810 Park Heights Avenue, Suite C5, Baltimore, MD 21215 USA
Copyright © 2013 Medifocus, Inc. All rights reserved.